Last reviewed · How we verify
Salmeterol MDI high — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Salmeterol MDI high (Salmeterol MDI high) — Boehringer Ingelheim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Salmeterol MDI high TARGET | Salmeterol MDI high | Boehringer Ingelheim | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Salmeterol MDI high CI watch — RSS
- Salmeterol MDI high CI watch — Atom
- Salmeterol MDI high CI watch — JSON
- Salmeterol MDI high alone — RSS
Cite this brief
Drug Landscape (2026). Salmeterol MDI high — Competitive Intelligence Brief. https://druglandscape.com/ci/salmeterol-mdi-high. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing